Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ: ATRA )

8.590 -0.130 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval. 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For November 12, 2024
Via Benzinga
Insights into Atara Biotherapeutics's Upcoming Earnings
Via Benzinga
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
From Atara Biotherapeutics, Inc.
Via Business Wire
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates
Via Benzinga
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns. 
Via Stocktwits
Exposures Product Safety
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Lower; Retail Sales Increase Less Than Expected
Via Benzinga
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Sidoti Events, LLC's Virtual November Micro-Cap Conference
Via ACCESSWIRE
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
Atara Biotherapeutics shares are trading higher by 20% Wednesday morning. The company announced a $36 million registered direct offering. 
Via Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.